With the development and regulatory approval of immune checkpoint inhibitors and adoptive
cell therapies, cancer immunotherapy has undergone a profound transformation over the …

Dendritic cell (DC)‐based cancer immunotherapy has exhibited remarkable clinical
prospects because DCs play a central role in initiating and regulating adaptive immune …

Unsatisfied tumor accumulation of chemotherapeutic drugs and a complicated
immunosuppressive microenvironment diminish the immune response rate and the …

Natural living materials serving as biotherapeutics exhibit great potential for treating various
diseases owing to their immunoactivity, tissue targeting, and other biological activities. In this …

Combined therapeutic strategies hold promises in augmenting antigen release to enhance
anti-tumor immunity, which have garnered attention in numerous scholarly reviews. Beyond …

Tertiary lymphoid structures (TLSs) primarily constructed by multiple immune cells can
effectively enhance tumor immune responses, but expediting the formation of TLSs is still an …

Immunotherapy is a new type of tumor treatment after surgery, radiotherapy and
chemotherapy, which can be used to manage and destroy tumor cells through activating or …

Tumor extracellular matrix (ECM) not only forms a physical barrier for T cells infiltration, but
also regulates multiple immunosuppressive pathways, which is an important reason for …

Dendritic cell (DC)-based vaccines have shown promise in adoptive cell therapy for
enhancing the antigen-specific response of antitumor immunity. However, their clinical …

In personalized cancer immunotherapy, developing an effective neoantigen nanovaccine
with high immunogenicity is a significant challenge. Traditional nanovaccine delivery …